Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.
Daniele Roberto GiacobbeLaura LabateChiara Russo ArtimagnellaCristina MarelliAlessio SignoriVincenzo Di PilatoChiara AldieriAlessandra BanderaFederica BrianoBruno CacopardoAlessandra CalabresiFederico Capra MarzaniAnna CarrettaAnnamaria CattelanLuca CeccarelliGiovanni CenderelloSilvia CorcioneAndrea CortegianiRosario CultreraFrancesco Giuseppe De RosaValerio Del BonoFilippo Del PuenteChiara FanelliFiorenza FavaDaniela FrancisciNicholas GeremiaLucia GrazianiAndrea LombardiAngela Raffaella LositoIvana MaidaAndrea MarinoMaria MazzitelliMarco MerliRoberta MonardoAlessandra MularoniChiara OltoliniCarlo PallottoEmanuele PontaliFrancesca RaffaelliMatteo RinaldiMarco RipaTeresa Antonia SantantonioFrancesco Saverio SerinoMichele SpinicciCarlo TortiEnrico Maria TrecarichiMario TumbarelloMalgorzata MikulskaMauro GiacominiAnna MarcheseAntonio VenaMatteo Bassettinull nullPublished in: Infectious diseases and therapy (2024)
Cefiderocol is mainly used for targeted treatment, although empirical therapies account for more than 25% of prescriptions, thus requiring dedicated standardization and guidance. The almost equal distribution of cefiderocol monotherapy and cefiderocol-based combination therapies underlines the need for further study to ascertain possible differences in efficacy between the two approaches.